Nutra Pharma Corporation
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
Recent News
-
Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings
Plantation, Florida--(Newsfile Corp. - June 8, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced that Dive
2021-06-08 6:00 AM EDT -
Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers
Plantation, Florida--(Newsfile Corp. - June 4, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away, Luxury Feet and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today their plans for increasing sales of their over-the-counter pain relievers through private label agreemen
2021-06-04 8:15 AM EDT -
Professional Snowboarder Jake Vedder Joins Nutra Pharma in Endorsing Nyloxin for Chronic Pain Relief
Plantation, Florida--(Newsfile Corp. - June 2, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that they had signed an agreement with professional snowboarder Jake Vedder as a celebrity endorser of Nyloxin for Chronic Pain relief. Nutra Pharma previously announced their plan
2021-06-02 8:56 AM EDT -
Nutra Pharma Provides Updates on Improvements of Manufacturing Capabilities
Plantation, Florida--(Newsfile Corp. - May 27, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on increasing their manufacturing capabilities for the pro
2021-05-27 9:00 AM EDT -
Nutra Pharma Announces Influencer and Social Media Campaign for Nyloxin and Pet Pain-Away
Plantation, Florida--(Newsfile Corp. - May 24, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today their plans for expanding the marketing of their over-the-counter pain relievers and anti-inflammatory products by working with influencers on several social media platforms. These wil
2021-05-24 9:45 AM EDT -
Nutra Pharma is Excited to Announce: Luxury Feet now Available on Amazon
Plantation, Florida--(Newsfile Corp. - April 15, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that their newest product, Luxury Feet, is available for purchase on Amazon.com. Luxury Feet is an o
2021-04-15 9:00 AM EDT -
Nutra Pharma Announces Distribution of Luxury Feet for the Relief of Pain from High Heels
Plantation, Florida--(Newsfile Corp. - March 16, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today their plans for the marketing and distribution of Luxury Feet; an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience
2021-03-16 8:30 AM EDT -
Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials
Plantation, Florida--(Newsfile Corp. - March 11, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on their work in improving their existing facilities for manufacturing and validation of their drug products; including their technologies for the treatment of Multi
2021-03-11 8:30 AM EST -
Nutra Pharma Provides Updates on Laboratory Upgrades and Certifications
Plantation, Florida--(Newsfile Corp. - February 23, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on their work in improving their existing facilities for manufacturing and validation of their drug products, including their technologies as potential countermeasures
2021-02-23 9:20 AM EST -
Nutra Pharma Announces New Intellectual Property Update and Engages Additional Intellectual Property Attorneys
Plantation, Florida--(Newsfile Corp. - February 12, 2021) - Nutra Pharma Corporation (OTC PINK: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that they are focusing on their intellectual property portfolio and have engaged their IP attorneys at Christopher
2021-02-12 8:45 AM EST